Question 1

Berapa harga saham Global Partners LP hari ini?

Accepted Answer

Harga semasa Global Partners LP ialah 50.26 USD — ia telah meningkat sebanyak 2.07% dalam 24 jam yang lepas. Lihat prestasi harga saham Global Partners LP dengan lebih teliti pada grafik lanjutan.

Question 2

Apakah simbol saham Global Partners LP?

Accepted Answer

Bergantung pada bursa, simbol saham mungkin berbeza. Sebagai contoh, di bursa NYSE, saham Global Partners LP diniagakan dengan simbol GLP.

Question 3

Adakah harga saham GLP sedang naik?

Accepted Answer

Saham GLP telah meningkat sebanyak 1.56% dalam minggu lepas, telah meningkat sebanyak 9.98% dalam bulan lepas, dan telah meningkat sebanyak 0.88% dalam tahun lepas. Lihat lebih banyak data pada grafik GLP.

Question 4

Apakah cadangan penganalisis untuk GLP?

Accepted Answer

Setakat 22 Mei 2026, daripada 2 cadangan penganalisis, majoriti memberi penarafan GLP sebagai hold.

Question 5

Apakah nilai pasaran GLP?

Accepted Answer

Setakat hari ini, GLP mempunyai kapitalisasi pasaran sebanyak 1.66B USD. Jelajahi senarai saham kami yang diatur mengikut kapitalisasi pasaran untuk membandingkan GLP dengan saham lain.

Question 6

Adakah GLP mengeluarkan laporan kewangan?

Accepted Answer

Ya, anda boleh menjejaki kewangan GLP dalam laporan tahunan dan suku tahunan di Profit.com.

Question 7

Bila tarikh laporan pendapatan seterusnya GLP?

Accepted Answer

GLP akan mengeluarkan laporan pendapatan seterusnya pada -. Jejak acara yang akan datang dengan Kalendar Pendapatan kami.

Question 8

Berapa pendapatan GLP untuk suku tahunan lepas?

Accepted Answer

GLP melaporkan pendapatan sebanyak $0.54 setiap saham untuk suku tahunan lepas, lebih rendah daripada anggaran $0.96 setiap saham, menghasilkan kejutan -43.75%. Pendapatan yang dianggarkan untuk suku tahunan akan datang adalah $0.33 setiap saham. Lihat butiran lanjut tentang pendapatan GLP di Profit.com.

Question 9

Berapa hasil GLP untuk suku tahunan lepas?

Accepted Answer

Hasil GLP untuk suku tahunan lepas ialah 5.32B USD, lebih rendah daripada anggaran 7.46B USD. Hasil yang dianggarkan untuk suku tahunan akan datang ialah 7.06B USD. Lihat lebih banyak statistik dalam laporan kewangan GLP di Profit.com.

Question 10

Berapa Pendapatan Bersih GLP untuk suku tahunan lepas?

Accepted Answer

Pendapatan bersih GLP untuk suku tahunan lepas adalah 64.74M USD, manakala suku tahunan sebelumnya menunjukkan pendapatan bersih sebanyak 20.13M USD, yang mencatatkan perubahan sebanyak 221.70%. Lihat lebih banyak statistik dalam laporan kewangan GLP di Profit.com.

Question 11

Adakah GLP membayar dividen?

Accepted Answer

Ya, dividen GLP dibayar setiap suku tahun. Dividen terakhir per saham ialah 3.03. Sehingga hari ini, Dividend Yield (TTM)% adalah 6.20%.

Question 12

Berapa ramai pekerja yang ada di GLP?

Accepted Answer

Sehingga 22 Mei 2026, GLP menggaji kira-kira 3265 pekerja. Lihat jika GLP berada dalam senarai majikan terbesar kami.

Question 13

Apakah EBITDA GLP?

Accepted Answer

EBITDA, yang mengukur prestasi operasi syarikat, mencerminkan peningkatan kecekapan. EBITDA GLP ialah 422.81M USD, dengan margin EBITDA semasa sebanyak 0.67%. Lihat lebih banyak statistik dalam laporan kewangan GLP di Profit.com.

Question 14

Bagaimana untuk membeli saham GLP?

Accepted Answer

Seperti saham lain, saham GLP diperdagangkan di bursa saham seperti NYSE. Cara paling mudah untuk membelinya adalah melalui broker saham dalam talian. Buka akaun, ikuti prosedur broker, dan mula berdagang. Sebagai alternatif, anda boleh berlatih berdagang saham Tesla di Profit.com dalam Playtrade Tournaments atau pilih broker yang disyorkan untuk berdagang terus.

Question 15

Patutkah saya melabur dalam saham GLP?

Accepted Answer

Melabur dalam saham memerlukan penyelidikan yang teliti, termasuk menganalisis kewangan syarikat, berita berkaitan, dan analisis teknikal. Pada masa ini, cadangan penganalisis teknikal Tesla menunjukkan penarafan hold.

Sebelum melabur dalam GLP, pertimbangkan untuk melanggan Profit PRO di mana anda boleh berlatih berdagang dalam Playtrade Tournaments, mengakses pandangan pasaran harian yang digerakkan oleh AI, menyalin Watchlists yang dipilih dengan teliti, dan mengikuti Portfolia Bilionaire.

Global Partners LP

Amazon launches GLP-1 weight loss program, promising'fast, convenient' access

Eli Lilly taps into its GLP-1 windfall, while Honeywell sheds a lower-margin unit

RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves - CNBC

As millions lose weight on GLP-1s, they're starting to turn to retailers to refresh their wardrobes

Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment

GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up

Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says - CNBC

Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients

Fancy clothes, mealtime alarms and Disney princess gigs: How GLP-1s are changing people's lives in unexpected ways

Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China

What the initial frenzy over GLP-1 drugs can teach us about the current market

What signal Lilly sends by stockpiling its GLP-1 weight loss pills ahead of FDA approval

Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

This top stock-picker spotted Nvidia and GLP-1s early — and made over 200%. Here’s what he’s buying now.

Half of GLP-1 users ditch their injections — and some are turning to other weight-loss methods instead

Novo Nordisk CEO explains why new GLP-1 pill expands access to the weight loss drugs

Novo Nordisk Launches $149 Wegovy Pill, Expanding Access to GLP-1 Weight-Loss Drugs

FDA approves first GLP-1 pill for weight loss - Axios

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk - CNBC

GRVT GLP Strategy Reopened, Funding Cap Raised to $7.5M on Grvt’s Decentralized Perpetual Platform

There’s still hope GLP-1 drugs could slow the second-biggest type of dementia

Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s as hoped, and the stock tumbles

Is GLP-1 the new AI? Drugmaker Eli Lilly briefly joined the $1 trillion market cap club.

Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s

Tariffs and GLP-1s are keeping people from dining out. An analyst tries to find the positives.

GLP-1 drugs could save millions of lives — and spark a pension crisis

Hacked Perp DEX GMX to Repay $44M to Arbitrum GLP Holders After Exploit

Why GLP-1s could become the "everything drug" - Axios

GMX Recovers $42 Million GLP Funds on Arbitrum After V1 Vulnerability Attack

GMX Hack Exploits GLP Token Vulnerability, Potential Partial Recovery of Stolen Ethereum

GMX Faces $40 Million V1 GLP Pool Exploit, Raising Questions on DeFi Leverage Security

GMX V1 Faces Possible Exploit Impacting GLP Pool Amid Ongoing Crypto Security Concerns in 2025

GMX V1 GLP Pool on Arbitrum Hit by $40M Attack; Trading Suspended to Protect Users

Market Voices: July Fed rate cut eyed, GLP-1s, Darden, Aflac, JPMorgan

Just how many Americans are taking GLP-1s now - Axios

Hims & Hers shares tumble 18% as margin miss adds to concerns about GLP-1 business

Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease - Fortune

What's next for GLP-1 weight-loss drugs in 2025? https://t.co/LPstciGZ32 https://t.co/mVitY14CTY

Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’

WeightWatchers’ stock soars after adding compounded GLP-1 treatment to its offering

Obesity drugs in kindergarten? Novo Nordisk GLP-1 drug works for kids as young as 6, study finds.

Obesity drugs’ next wave: These companies could snag 20% of GLP-1 market, analysts say

For Alzheimer’s patients, this Novo Nordisk GLP-1 drug slows cognitive decline, study finds

Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says - CNBC

Zealand Pharma shares surge after positive results of weight-loss drug that could contend with GLP-1s

Ares Management exploring deal with GLP Capital Partners - Bloomberg

Healthy Returns: 1 in 8 adults have taken Ozempic or other GLP-1s, survey says - CNBC

GLP Capital Partners raises $1.4 bln for its China Income Fund XII https://t.co/qtW1H4tSch https://t.co/eFTinyLBlC

LifeMD’s stock soars 13% as company and Medifast to create weight-management program that includes GLP-1 drugs

Soalan Lazim